Fig. 4.

Monte Carlo simulation for reaching target mutant prevention concentration (MPC; 1 μg/ml) with various doses. Trough concentration was calculated using the interim population pharmacokinetics parameters of Model 2 in Table 3 and patient covariates randomly re-sampled from real CL_CR values (34.4–133.2 ml/min, n = 55). Trough concentration was simulated for 1,000 putative cases, and the probability of reaching above MPC was calculated for various garenoxacin dosing regimens (doses of 100, 200, 250, 300, 350, 400, and 600 mg). The typical MPC value was <1 μg/ml for S. aureus, S. pneumoniae, and H. influenzae, including resistant strains